While Dr Reddy's (DRRD) Q3 positively surprised us with expansion in gross margin (+300bps QoQ on better revenue mix), guidance of relatively softer Q4 on(1) delay in launch/ approval of key products (gAloxi, gGleevec) in US and (2) manufacturing issues in one of its key product was disapp..